Breast cancer stem cells: Obstacles to therapy

Smalley, Matthew J.; Piggott, Luke; Clarkson, Richard W. E.

doi:10.1016/j.canlet.2012.04.023

Cited by 64 publications

(74 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…90 These are the breast cancer stem cells (BCSCs) which are often characterized based on their ability to initiate tumors in immunocompromised or syngeneic mice, self-renewal capacity as measured by tumor formation in secondary mice and also the ability to differentiate into the non-self-renewing cells, which constitute the tumor bulk. 91 BCSCs are commonly identified using the characteristic CD44 + /CD24 -/low marker profile or Aldefluor assays.…”

Section: Micrornas and Breast Cancer Stem Cellsmentioning

confidence: 99%

Role of microRNAs in breast cancer

Singh

Mo²

2013

Cancer Biology & Therapy

141

109

View full text Add to dashboard Cite

Section: Micrornas and Breast Cancer Stem Cellsmentioning

confidence: 99%

Role of microRNAs in breast cancer

Singh

Mo²

2013

Cancer Biology & Therapy

141

109

View full text Add to dashboard Cite

“…DLGAP5 has been proposed to be a target of the neurogenic locus notch homolog protein 3 signaling pathway (59), which is associated with embryogenesis and breast cancer tumorigenesis (60). DLAGP5 is reportedly a member of the cervical cancer interaction network (61), and has been revealed to be overexpressed in ovarian carcinoma compared with in normal ovarian epithelium (59).…”

Section: Cancer Typementioning

confidence: 99%

Network analysis revealed aurora kinase dysregulation in five gynecological types of cancer

Sethi

Mishra

2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. Gene markers are crucial for cancer prognosis and treatment. Previous studies have placed greater emphasis on individual diagnostic genes, thereby ignoring systemic-level attributes across diseases. Female-specific cells namely, breast, endometrium, cervical, ovarian and vulvar cells are highly susceptible to cancer. To date, a limited number of molecular studies have been performed that evaluate common biological processes across gynecological types of cancer. Differentially expressed genes in breast, cervical, endometrial, vulvar and ovarian cancer were utilized to construct protein-protein interaction networks, and to identify a common module across the five cancer types. A single common module with 8 nodes and 26 edges was mined among the five cancer systems. In total, four hub genes were present across the five cancer gene sets. Genes in the common module were enriched for the common pathways and associated diseases. The aurora kinase pathway was revealed to be conserved across the five cancer types surveyed. The present study, therefore, revealed that the aurora kinase pathway has a crucial function in the pathogenesis of the five aforementioned gynecological types of cancer through cross-tumor conservation.

show abstract

“…Overactivation of the Notch pathway has been implicated particularly in breast CSCs, possibly by influencing the EMT and contributing to the invasiveness of the CSCs. [26] One group investigated the effects of the bioactive compound psoralidin on Notch signaling in a breast cancer model. The plant-derived drug inhibited Notch signaling in both bulk tumor and CSCs, resulting in decreased mammosphere formation, upregulation of pro-apoptotic proteins, and inhibition of CSC proliferation.…”

Section: Regulating Csc Signaling Pathwaysmentioning

confidence: 99%

Therapeutic strategies for targeting cancer stem cells

Kim¹,

Siegler²,

Siriwon³

et al. 2016

JCMT

View full text Add to dashboard Cite

The therapeutic limitations of conventional chemotherapeutic drugs present a challenge for cancer therapy; these shortcomings are largely attributed to the ability of cancer cells to repopulate and metastasize after initial therapies. Compelling evidence suggests that cancer stem cells (CSCs) have a crucial impact in current shortcomings of cancer therapy because they are largely responsible for tumor initiation, relapse, metastasis, and chemo-resistance. Thus, a better understanding of the properties and mechanisms underlying CSC resistance to treatments is necessary to improve patient outcomes and survival rates. In this review, the authors characterize and compare different CSC-specific biomarkers that are present in various types of tumors. We further discuss multiple targeting approaches currently in preclinical or clinical testing that show great potential for targeting CSCs. This review discusses numerous strategies to eliminate CSCs by targeting surface biomarkers, regulating CSC-associated oncogenes and signaling pathways, inhibiting drug-efflux pumps involved in drug resistance, modulating the tumor microenvironment and immune system, and applying drug combination therapy using nanomedicine.

show abstract

Breast cancer stem cells: Obstacles to therapy

Cited by 64 publications

References 63 publications

Role of microRNAs in breast cancer

Role of microRNAs in breast cancer

Network analysis revealed aurora kinase dysregulation in five gynecological types of cancer

Therapeutic strategies for targeting cancer stem cells

Contact Info

Product

Resources

About